

# BBS-Bioactive Bone Substitutes Plc has received subscription undertakings and supplements the Investor Memorandum relating to the rights offering and publishes updated Basic Information Document

BBS-Bioactive Bone Substitutes Plc | Company Release | August 30, 2024 at 18:30:00 EEST

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.**

**BBS-Bioactive Bone Substitutes Plc has received subscription undertakings and supplements the Investor Memorandum dated August 26, 2024, relating to the rights offering and publishes updated Basic Information Document**

BBS-Bioactive Bone Substitutes Plc ("BBS" or the "Company") has announced on August 26, 2024, that based on authorization granted by the Annual General Meeting on June 13, 2024, the Board of Directors of the Company has decided to arrange a rights offering totalling approximately EUR 2.4 million (the "Offering"). The Offering consists of a maximum of 8,298,870 new shares (the "Offer Shares").

## Subscription undertakings

Certain current shareholders of the Company mentioned below have provided subscription undertakings, on the basis of which they have committed to subscribe for approximately 16.9 percent of the Offer Shares offered in the Offering, i.e. they have committed to participate in the Offering with 0.4 million euros. The Company has received the following subscription undertakings to subscribe for Offer Shares in connection with the Offering:

Shareholder subscribing for Offer Shares	Subscription undertaking (shares)	Subscription undertaking (EUR)
Panvest Oy	521,836	151,332.44
Finha Capital Oy	362,068	104,999.72
Riverfort Global Opportunities PCC Limited	258,620	74,999.80
Halonen family	155,172	44,999.88
Pekka Jalovaara	34,482	9,999.78
Jyrki Halonen	34,482	9,999.78
Jarmo Halonen	34,482	9,999.78
<b>Total</b>	<b>1,401,142</b>	<b>406,331.18</b>

The Company has not received or requested collaterals from the parties that have committed to subscribe for the Offer Shares in the Offering on the basis of subscription undertakings.

## **Investor Memorandum and Basic Information Document**

The Company has published on August 26, 2024, in connection with the Offering, the Investor Memorandum (“Investor Memorandum”) as well as the Basic Information Document in accordance with Chapter 3, Section 2 of the Finnish Securities Markets Act (746/2012, as amended) (“Basic Information Document”). The Company has today published a supplement to the Investor Memorandum and the updated Basic Information Document, both of which are available on the Company’s website <https://www.bbs-artebone.fi/investors/share-issue-2024-9/>.

The supplements to the documents includes information regarding the subscription undertakings announced in this Company Announcement.

## **IMPORTANT NOTICE**

This release or the information contained therein shall not be distributed, directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or the United States. The information contained in this release do not constitute an offer of, or invitation to purchase any securities in any area, where offering, procurement of or selling such securities would be unlawful prior to registration or exemption from registration or any other approval required by the securities regulation in such area. This release is not an offer for sale of securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended, and the rules and regulations issued by virtue of it. BBS has not registered, and does not intend to register, any offering of securities in the United States. No actions have been taken to register the shares or the offering anywhere else than in Finland.

The information contained herein shall not constitute an offer of, or invitation to purchase any securities in any jurisdiction. This release is not a prospectus and does not constitute any offer, invitation or investment advice to subscribe for or purchase securities. Investors should not subscribe for or purchase any securities or make any investment decisions referred to herein except based on information contained in The Investor Memorandum and the Basic Information Document issued by BBS.

### **For more information, please contact:**

Juliusz Rakowski, CEO  
+358 50 448 5132  
[juliusz.rakowski@bbs-artebone.fi](mailto:juliusz.rakowski@bbs-artebone.fi)

### **Certified Advisor:**

Nordic Certified Adviser AB,  
+46 70 551 67 29,  
[info@certifiedadviser.se](mailto:info@certifiedadviser.se)

### **Distribution**

Nasdaq Helsinki

<https://www.bbs-artebone.fi/>

### **BBS in brief**

*BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.*

*BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.*

More information: [www.bbs-artebone.fi](http://www.bbs-artebone.fi)

### **Attachments**

[BBS Basic Information Document 30 8 2024](#)

[Investor Memorandum Supplement BBS 30 8 2024](#)